By AAMER MADHANI

WASHINGTON (AP) — President Joe Biden is set to meet on Monday with a group of 10 Republican senators who have proposed $618 billion in coronavirus relief, about a third of the $1.9 trillion he is seeking as congressional Democrats are poised to move ahead without Republican support.

The Republicans propose slimmer benefits, including $1,000 in direct payments to individuals earning up to $40,000 a year, or $80,000 for couples, according to a draft obtained by The Associated Press. The proposal would begin to phase out the benefit after that, with no payments for those individuals earning more than $50,000, or $100,000 for couples. That’s less than Biden’s proposal for $1,400 direct payments at higher incomes levels.

The cornerstone of the GOP plan appears to be $160 billion for the health care response — vaccine distribution, a “massive expansion” of testing, protective gear and funds for rural hospitals, according to the draft.

Others elements of the package are similar but at far lesser amounts, with $20 billion to reopen schools and $40 billion for Paycheck Protection Program business aid.

An invitation to the GOP senators to meet at the White House came hours after the lawmakers sent Biden a letter on Sunday urging him to negotiate rather than try to ram through his relief package solely on Democratic votes. The House and Senate are on track to vote as soon as this week on a budget resolution, which would lay the groundwork for passing an aid package under rules requiring only a simple majority vote in the closely divided Senate.

The goal is for passage by March, when extra unemployment assistance and other pandemic aid expires. The meeting to be hosted by Biden would amount to the most public involvement for the president in the negotiations for the next round of virus relief. Democratic and Republican lawmakers are far apart in their proposals for assistance.

White House press secretary Jen Psaki said Sunday that Biden had spoken with the leader of the group, Sen. Susan Collins, R-Maine. Though Biden wants “a full exchange of views,” Psaki reiterated that the president remains in favor of moving forward with a far-reaching relief package.

“With the virus posing a grave threat to the country, and economic conditions grim for so many, the need for action is urgent, and the scale of what must be done is large,” Psaki said.

In challenging Biden to fulfill his pledge of unity, the group said in its letter that its counterproposal will include $160 billion for vaccines, testing, treatment and personal protective equipment and call for more targeted relief than Biden’s plan to issue $1,400 stimulus checks for most Americans.

Winning the support of 10 Republicans would be significant for Biden in the 50-50 Senate where Vice President Kamala Harris is the tie-breaker. If all Democrats were to back an eventual compromise bill, the legislation would reach the 60-vote threshold necessary to overcome potential blocking efforts and pass under regular Senate procedures.

“In the spirit of bipartisanship and unity, we have developed a COVID-19 relief framework that builds on prior COVID assistance laws, all of which passed with bipartisan support,” the Republican senators wrote. “Our proposal reflects many of your stated priorities, and with your support, we believe that this plan could be approved quickly by Congress with bipartisan support.”

The plea for Biden to give bipartisan negotiations more time comes as the president has shown signs of impatience as the more liberal wing of his party considers passing the relief package through a process known as budget reconciliation. That would allow the bill to advance with only the backing of his Democratic majority.

“If you can’t find bipartisan compromise on COVID-19, I don’t know where you can find it,” said Ohio Sen. Rob Portman, who also signed the letter.

But even as Biden extended the invitation to the Republican lawmakers, Psaki said that $1,400 relief checks, substantial funding for reopening schools, aid to small businesses and hurting families, and more “is badly needed.”

“As leading economists have said, the danger now is not in doing too much: it is in doing too little,” Psaki said. “Americans of both parties are looking to their leaders to meet the moment.”

Biden also spoke on Sunday with House Speaker Nancy Pelosi and Senate Majority Leader Chuck Schumer, who are facing a growing push from the more liberal Democratic members to move forward with Biden’s legislation with or without Republican support.

The other GOP senators invited to meet with Biden are Lisa Murkowski of Alaska, Mitt Romney of Utah, Shelley Moore Capito of West Virginia, Todd Young of Indiana, Jerry Moran of Kansas, Mike Rounds of South Dakota, and Thom Tillis of North Carolina.

Brian Deese, the top White House economic adviser leading the administration’s outreach to Congress, indicated the White House could be open to negotiating on further limiting who would receive stimulus checks. Portman suggested the checks should go to individuals who make no more than $50,000 per year and families capped at $100,000 per year.

Under the Biden plan, families with incomes up to $300,000 could receive some stimulus money.

“That is certainly a place that we’re willing to sit down and think about, are there ways to make the entire package more effective?” Deese said.

As a candidate, Biden predicted his decades in the Senate and his eight years as Barack Obama’s vice president gave him credibility as a deal-maker and would help him bring Republicans and Democrats to consensus on the most important matters facing the country.

But less than two weeks into his presidency, Biden showed frustration with the pace of negotiations at a time when the economy exhibited further evidence of wear from the pandemic. Last week, 847,000 Americans applied for unemployment benefits, a sign that layoffs remain high as the coronavirus pandemic continues to rage.

“I support passing COVID relief with support from Republicans if we can get it. But the COVID relief has to pass — no ifs, ands or buts,” Biden said on Friday.

In the letter, the Republican lawmakers reminded Biden that in his inaugural address, he proclaimed that the challenges facing the nation require “the most elusive of things in a democracy: Unity.”

Sen. Bill Cassidy, R-La., separately criticized the current Biden plan as “chock-full of handouts and payoffs to Democratic constituency groups.”

“You want the patina of bipartisanship … so that’s not unity,” Cassidy said.

By LAURAN NEERGAARD and LINDA A. JOHNSON

AP – Johnson & Johnson’s long-awaited vaccine appears to protect against COVID-19 with just one shot – not as strong as some two-shot rivals but still potentially helpful for a world in dire need of more doses.

J&J said Friday that in the U.S. and seven other countries, the single-shot vaccine was 66% effective overall at preventing moderate to severe illness, and much more protective — 85% — against the most serious symptoms.

There was some geographic variation. The vaccine worked better in the U.S. — 72% effective against moderate to severe COVID-19 – compared to 57% in South Africa, where it was up against an easier-to-spread mutated virus.

“Gambling on one dose was certainly worthwhile,” Dr. Mathai Mammen, global research chief for J&J’s Janssen Pharmaceutical unit, told The Associated Press.

With vaccinations off to a rocky start globally, experts had been counting on a one-dose vaccine that would stretch scarce supplies and avoid the logistics nightmare of getting people to return for boosters.

But with some other competing vaccines shown to be 95% effective after two doses, at question is whether somewhat less protection is an acceptable tradeoff to get more shots in arms quickly.

“Frankly, simple is beautiful,” said Dr. Matt Hepburn of Operation Warp Speed, the U.S. government’s vaccine initiative.

The company said within a week, it will file an application for emergency use in the U.S., and then abroad. It expects to supply 100 million doses to the U.S. by June — and a billion doses globally by the end of the year. J&J wouldn’t say exactly how much could be ready to ship as soon as U.S. authorities give the green light.

These are preliminary findings from a study of 44,000 volunteers that isn’t completed yet. Researchers tracked illnesses starting 28 days after vaccination – about the time when, if participants were getting a two-dose variety instead, they would have needed another shot.

After day 28, no one who got vaccinated needed hospitalization or died regardless of whether they were exposed to “regular COVID or these particularly nasty variants,” Mammen said. When the vaccinated did become infected, they had a milder illness.

Defeating the scourge that has killed more than 2 million people worldwide will require vaccinating billions, and the shots being rolled out in different countries so far all require two doses a few weeks apart for full protection. Early data is mixed on exactly how well all the different kinds work, but shots made by Pfizer and Moderna appear to be about 95% protective after the second dose.

That makes for a dilemma: Wouldn’t people given a choice want a vaccine found to offer much more protection?

J&J’s Mammen said direct comparisons are difficult because the Pfizer and Moderna vaccines weren’t tested when the pandemic was so severe, with record levels of hospitalizations and deaths plus mutant versions of the virus sweeping some countries.

Dr. Anthony Fauci, the top U.S. infectious disease official, called that a messaging challenge — because the priority is to protect people from hospitalization and death, which J&J’s vaccine appears to do. Especially in places where it’s hard to get people to return for their second dose, the one-dose version could play a key role.

Maybe more important is “a wake-up call” from the study that mutating viruses can challenge vaccines. And the best way to prevent more mutations is “by vaccinating as many people as you possibly can,” Fauci said.

All COVID-19 vaccines train the body to recognize the new coronavirus, usually by spotting the spikey protein that coats it. But they’re made in very different ways.

J&J’s shot uses a cold virus like a Trojan horse to carry the spike gene into the body, where cells make harmless copies of the protein to prime the immune system in case the real virus comes along. It’s the same technology the company used in making a successful Ebola vaccine.

Rival AstraZeneca makes a similar cold virus vaccine that requires two doses. Both the AstraZeneca and J&J vaccines can be stored in a refrigerator, making them easier to ship and to use in developing countries than the frozen kind made by Pfizer and Moderna.

It’s not clear exactly how well the AstraZeneca version, being used in Britain and several other countries, works. Tests in Britain, South Africa and Brazil suggested two doses are about 70% effective although there are questions about how much protection older adults get. An ongoing U.S. study may provide more information.

J&J said its vaccine works consistently in a broad range of people: A third of participants were over age 60, and more than 40% had other illnesses putting them at risk of severe COVID-19, including obesity, diabetes and HIV.

J&J said the vaccine is safe, with reactions similar to other COVID-19 shots such as fever that occur when the immune system is revved up.

While it released few details, the company said there were no serious allergic reactions. But occasionally other COVID-19 vaccines trigger such reactions, which can be reversed if promptly treated – and authorities have warned people to be on the lookout regardless of which type of vaccine is used.

J&J had hedged its bets with a study of a two-dose version of its vaccine, which is still underway.

Friday’s interim results come on the heels of another vaccine in final testing. Novavax reported this week that its vaccine appears 89% effective in a U.K. study and that it also seems to work — though not as well — against new mutated versions of the virus circulating in Britain and South Africa. A larger study in the U.S. and Mexico is still enrolling volunteers.

Wall Street appeared dissatisfied with J&J’s results, with shares dropping 4.2% in early trading, a rare big drop for the world’s biggest maker of health care products. Shares were down $4.07, or 2.4%, at $165.09 in mid-morning trading.

In contrast, tiny Novavax saw shares skyrocket, jumping 71% to $229.72 in mid-morning trading.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

By EMILY WANG FUJIYAMA

WUHAN, China (AP) — A World Health Organization team emerged from quarantine in the Chinese city of Wuhan on Thursday to start field work in a fact-finding mission on the origins of the virus that caused the COVID-19 pandemic.

The researchers, who were required to isolate for 14 days after arriving in China, left their quarantine hotel with their luggage — including at least four yoga mats — in the midafternoon and headed to another hotel.

The mission has become politically charged, as China seeks to avoid blame for alleged missteps in its early response to the outbreak. A major question is where the Chinese side will allow the researchers to go and whom they will be able to talk to.

Yellow barriers blocked the entrance to the hotel, keeping the media at a distance. Before the researchers boarded their bus, workers wearing protective outfits and face shields could be seen loading their luggage, including two musical instruments and a dumbbell.

Hotel staff waved goodbye to the researchers, who were wearing face masks. The bus driver wore a full-body white protective suit. They drove about 30 minutes to a lakeside Hilton resort-like hotel.

Former WHO official Keiji Fukuda, who is not part of the team in Wuhan, has cautioned against expecting any breakthroughs, saying it may take years before any firm conclusions can be made about the virus’s origin.

“This is now well over a year past when it all started,” he said earlier this month. “So much of the physical evidence is going to be gone. The memories of people are imprecise and probably the physical layouts of many places are going to be different than they were.”

Among the places they might visit are the Huanan Seafood Market, which was linked to many of the first cases, as well as research institutes and hospitals that treated patients at the height of the outbreak.

It hasn’t been disclosed whether they will leave Wuhan. One possible source of the virus is bats in caves in rural Yunnan province, about 1,600 kilometers (1,000 miles) southwest of Wuhan.

Foreign Ministry spokesperson Zhao Lijian said the experts would have talks, visits and inspections in China to carry out virus-tracing exchanges and cooperation. He did not provide any details.

The mission only came about after considerable wrangling between the two sides that led to a rare complaint from the WHO that China was taking too long to make the final arrangements.

China, which has strongly opposed an independent investigation it could not fully control, said the matter was complicated and that Chinese medical staff were preoccupied with new virus clusters in Beijing, Shanghai and other cities.

While the WHO was criticized early on, especially by the U.S., for not being critical enough of the Chinese response, it recently accused China and other countries of moving too slowly at the start of the outbreak, drawing a rare admission from the Chinese side that it could have done better.

Overall, though, China has staunchly defended its response, possibly out of concern over the reputational or even financial costs if it were found lacking.

Chinese officials and state media have also tried to cast doubt on whether the virus even started in China. Most experts believe it came from bats, possibly in southwest China or neighboring areas of Southeast Asia, before being passed to another animal and then to humans.

The origins search will try to determine where and exactly how that happened.

White House Press Secretary Jen Psaki expressed concern Wednesday about what she called “misinformation” coming out of China, adding that the U.S. supports a robust international investigation.

“It’s imperative that we get to the bottom of the early days of the pandemic in China,” she said.

Zhao responded that any negative speculation and politicized interpretation of the mission is inappropriate.

“We hope the U.S. can work with the Chinese side in a responsible manner, respect facts and science, and respect the hard work of the international expert team in tracing the origin of the virus,” he said, “so that they can conduct scientific research on the virus tracing without any political interference.”

___

Associated Press photographer Ng Han Guan contributed to this report.